Avandia
Motley Rice is litigating cases involving individuals who have suffered a heart attack, ischemic stroke or other cardiac condition while taking Avandia for diabetes. Avandia is a drug used to treat patients suffering from type 2 diabetes, also referred to as adult onset diabetes. Manufactured by GlaxoSmithKline, Avandia is a member of a relatively new class of diabetes medication called thiazolidinediones.
Avandia, like other thiazolidinediones, can cause fluid retention which may lead to heart failure. Injuries associated with Avandia use can include: If you or a loved one may have experienced any of the above symptoms while taking Avandia, please contact attorney and Avandia litigation Plaintiffs' Steering Committee member Fred Thompson or attorney Lynn Seithel by email or call +1 800.768.4026.
Avandia seeks to treat type 2 diabetes by decreasing insulin resistance to help the body control its blood sugar level, thus decreasing the body's need for additional insulin. Thiazolidinediones, including Avandia, have been linked to liver and cardiovascular complications. Avandia was approved by the FDA and introduced to the U.S. market on April 4, 2000. Current Avandia labels warn of the increased risk of congestive heart failure and serious liver problems. The first drug classified as a thiazolidinedione, Rezulin, was removed from the U.S. market on March 21, 2000 after more than 60 people died from liver failure. In May 2007, the New England Journal of Medicine published an analysis linking Avandia to increased risk of heart attacks. The meta-analysis reviewed 42 studies and found patients taking Avandia® to be at a 43% higher risk of heart attack or other cardiovascular-related risk. The FDA issued a May 21, 2007, alert about safety data from clinical trials that showed a potentially significant increase in the risk of heart attack and heart-related deaths in patients taking Avandia. The FDA advised patients to discuss treatment options with their doctor if they are taking Avandia and have underlying heart disease or are at high risk of heart attack.Additionally, prominent scientists have raised concerns about Avandia, specifically whether the drug’s safety should have been more extensively tested before being offered to patients. “The FDA rushed to approve Avandia, " said Dr. Nissen, a renowned cardiologist at the Cleveland Clinic, at the June 2007 annual meeting for the American Diabetes Association. "In my view that was a regulatory mistake. A strong safety signal of excess cardiovascular events was ignored."Symptoms
Drug History and Serious Adverse Reactions
